Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | SLC5A1 | P13866 | 5/20 | 0.40 |
| ▸ | SLC5A2 | P31639 | 5/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL403092 | 0.91 | SLC6A2 (0.48) | SLC6A2TACR1KCNA5LTA4HSIGMAR1 | |
| SCHEMBL19145004 | 0.91 | SLC6A2 (0.69) | SLC6A2PDE4DLGALS8BCHE | |
| SCHEMBL12803176 | 0.87 | SLC6A2 (0.46) | SLC6A2SLC5A1SLC5A2 | |
| SCHEMBL22367763 | 0.87 | SLC6A2 (0.46) | SLC6A2SLC5A1SLC5A2 | |
| SCHEMBL14363012 | 0.84 | SLC6A2 (0.43) | SLC6A2TACR1KCNA5BCHE | |
| SCHEMBL12516420 | 0.81 | SLC6A2 (0.62) | SLC6A2PDE4DBCHE | |
| SCHEMBL21096772 | 0.81 | SLC6A2 (0.62) | SLC6A2PDE4DBCHE | |
| SCHEMBL2220309 | 0.81 | SLC6A2 (0.62) | SLC6A2PDE4DBCHE | |
| SCHEMBL8717719 | 0.81 | SLC6A2 (0.54) | SLC6A2PDE4DLGALS8BCHE | |
| SCHEMBL402639 | 0.81 | SLC6A2 (0.60) | SLC6A2PDE4DLGALS8BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065153-A1 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF | SANOFI-AVENTIS (FR) | 2012-03-15 | — | — | US | disclosed |
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | SANOFI-AVENTIS (FR) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065153-A1 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF | HPSE, HAAO, HEXD | SLC6A2 2728/4885PDE4D 3160/4885SLC5A1 380/4885 |
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | HPSE, HAAO, HEXD | SLC6A2 2759/4885PDE4D 3189/4885SLC5A1 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.